ShuchiGulatiMDMSc, FACP
Oncology • Sacramento, CAGenitourinary Oncology
Assistant Professor, Hematology and Oncology, University of California Davis Comprehensive Cancer Center
Dr. Gulati is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UC Davis Comprehensive Cancer Center
4501 X Street
Sacramento, CA 95817
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2015 - 2018
Tower HealthResidency, Internal Medicine, 2010 - 2012
Cleveland Clinic Foundation/Fairview HospitalInternship, Internal Medicine, 2009 - 2010
Indira Gandhi Medical CollegeClass of 2008
Certifications & Licensure
CA State Medical License 2022 - 2026
OH State Medical License 2009 - 2023
PA State Medical License 2010 - 2012
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- Defining obesity in the context of cancer: thinking beyond body mass index.Shuchi Gulati, William J Murphy
Trends in Cancer. 2025-02-14 - Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma.Megan E Bischoff, Behrouz Shamsaei, Juechen Yang, Dina Secic, Bhargav Vemuri
Cancer Discovery. 2025-02-07 - 1 citationsDifferences in mutations across tumour sizes in clear-cell renal cell carcinoma.Steven M Monda, Benjamin W Carney, Allison M May, Shuchi Gulati, Simpa S Salami
BJU International. 2025-02-01
Press Mentions
Adjuvant Everolimus Offers No Survival Benefit in Non–Clear Cell RCCAugust 30th, 2024- Study Compares the Cost and Efficacy of Anticoagulant TherapiesJanuary 4th, 2023
- Direct Oral Anticoagulants More Effective and Cost-Effective for Treating Cancer-Associated ThrombosisDecember 27th, 2022
- Join now to see all
Grant Support
- Combination of Transcriptomic and Metallomic Biomarkers for Risk Assessment in Locoregional Clear Cell Renal Cell CarcinomaUNIVERSITY OF CALIFORNIA AT DAVIS2022–2027
Professional Memberships
- Associate
- Member
- SITCMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
